<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449929</url>
  </required_header>
  <id_info>
    <org_study_id>114915</org_study_id>
    <nct_id>NCT01449929</nct_id>
  </id_info>
  <brief_title>Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects</brief_title>
  <acronym>FLAMINGO</acronym>
  <official_title>A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral na誰ve Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy
      (ART)-na誰ve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg
      once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once
      daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside
      reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or
      tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and
      background NRTI selection. The primary analysis will take place after the last subject
      completes 48 weeks on therapy; an additional analysis will be conducted after the last
      subject completes Week 96 on study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ING114915 is a Phase IIIb randomized, open-label, active-controlled, multicentre, parallel
      group, fully-powered non-inferiority study. The study will be conducted in approximately 468
      HIV-1 infected ART-na誰ve subjects. Subjects will be randomized 1:1 to receive DTG 50 mg once
      daily (approximately 234 subjects) or DRV/r 800 mg/100 mg once daily (approximately 234
      subjects), each in combination with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC).
      The primary analysis will take place after the last subject completes 48 weeks on therapy; an
      additional analysis will be conducted after the last subject completes Week 96 on study.

      Subjects who fulfil eligibility requirements will be randomized 1:1 to receive DTG 50 mg once
      daily or DRV/r 800 mg/100 mg once daily. In order to achieve balance across the two treatment
      groups of the study, randomization will be stratified by: screening plasma HIV-1 RNA &gt;/
      100,000 copies/mL (c/mL) or &gt; 100,000 c/mL and background dual NRTI (ABC/3TC or TDF/FTC) The
      DTG and DRV/r doses will be administered in an open-label fashion throughout the study.

      Subjects randomized to receive DTG and who successfully complete 96 weeks of treatment will
      continue to have access to DTG until either it is locally approved and commercially
      available, the patient no longer derives clinical benefit, the patient meets a
      protocol-defined reason for discontinuation or until development of DTG is terminated.
      Subjects randomized to the DRV/r arm will receive DRV/r through their Week 96 visit, after
      which they will be discontinued from the study and will need to make alternative arrangements
      to access antiretroviral medication. All subjects will receive background dual-NRTI therapy
      through their Week 96 visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2011</start_date>
  <completion_date type="Actual">December 26, 2016</completion_date>
  <primary_completion_date type="Actual">April 22, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;50 Copies/Milliliter (c/mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) &quot;snapshot&quot; algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Virologic Suppression (&lt;50 Copies/mL) Through Week 48</measure>
    <time_frame>From Baseline through Week 48</time_frame>
    <description>The time to viral suppression (i.e. first viral load value &lt;50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &lt;400 c/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with Plasma HIV-1 RNA &lt;400 c/mL at Week 48 was assessed MSDF, as codified by the FDA &quot;snapshot&quot; algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
    <description>Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ and CD8+ Cell Counts</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 36 and 48 for CD4+ and Baseline and Weeks 4, 12, 24 and 48 for CD8+</time_frame>
    <description>Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48</measure>
    <time_frame>From Baseline through Week 48</time_frame>
    <description>Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment*visit interaction and Baseline LDL cholesterol*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48</measure>
    <time_frame>From Baseline through Week 48</time_frame>
    <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities</measure>
    <time_frame>From Baseline through Week 48</time_frame>
    <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)</measure>
    <time_frame>Baseline until PDVF up to Week 48</time_frame>
    <description>An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA &gt;200 c/mL &gt;=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48</measure>
    <time_frame>Baseline, Week 4, Week 24, and Week 48</time_frame>
    <description>SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participant's quality of life over that period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
    <description>The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48</measure>
    <time_frame>Baseline, Week 24, and Week 48</time_frame>
    <description>The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48</measure>
    <time_frame>Week 4, Week 24, and Week 48</time_frame>
    <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48</measure>
    <time_frame>Week 4, Week 24, and Week 48</time_frame>
    <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48</measure>
    <time_frame>Week 4, Week 24, and Week 48</time_frame>
    <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>dolutegravir 50mg once daily (OAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>darunavir 800mg OAD in combination with ritonavir 100mg OAD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir 50 mg OAD</intervention_name>
    <description>1 x 50 mg tablet OAD</description>
    <arm_group_label>dolutegravir 50mg once daily (OAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir 800mg OAD</intervention_name>
    <description>2 x 400mg tablets OAD</description>
    <arm_group_label>darunavir 800mg OAD in combination with ritonavir 100mg OAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir 100mg OAD</intervention_name>
    <description>1 x 100mg tablet OAD</description>
    <arm_group_label>darunavir 800mg OAD in combination with ritonavir 100mg OAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible
             to enter and participate in the study if she is (1) non-childbearing potential, (2)
             child bearing potential with negative pregnancy test at screening and Day 1 and agrees
             to use protocol-specified methods of birth control while on study.

          -  HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to
             1000copies/mL

          -  Antiretroviral-na誰ve (less than or equal to 10 days of prior therapy with any
             antiretroviral agent following a diagnosis of HIV-1 infection)

          -  Signed and dated written informed consent is obtained from the subject or the
             subject's legal representative prior to screening

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Any evidence of an active Centers for Disease and Prevention Control (CDC) Category C
             disease [CDC, 1993], except cutaneous Kaposi's sarcoma not requiring systemic therapy

          -  Subjects with moderate to severe hepatic impairment (Class B or C) as determined by
             Child-Pugh classification

          -  Anticipated need for Hepatitis C virus (HCV) therapy during the study

          -  History or presence of allergy or intolerance to the study drugs or their components
             or drugs of their class

          -  History of malignancy within the past 5 years or ongoing malignancy other than
             cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous
             squamous cell carcinoma; other localized malignancies require agreement between the
             investigator and the Study medical monitor for inclusion of the subject

          -  Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

          -  Treatment with any of the following agents within 28 days of Screening: radiation
             therapy; cytotoxic chemotherapeutic agents; any immunomodulators

          -  Treatment with any agent, except recognized ART as allowed above, with documented
             activity against HIV-1 in vitro within 28 days of first dose of investigational
             product

          -  Exposure to an experimental drug or experimental vaccine within either 28 days, 5
             half-lives of the test agent, or twice the duration of the biological effect of the
             test agent, whichever is longer, prior to the first dose of investigational product

          -  Any evidence of primary viral resistance based on the presence of any major
             resistance-associated mutation [IAS-USA, 2010] in the Screening result or, if known,
             any historical resistance test result

          -  Any verified Grade 4 laboratory abnormality. Any acute laboratory abnormality at
             Screening, which, in the opinion of the Investigator, would preclude the subject's
             participation in the study of an investigational compound is exclusionary

          -  Alanine aminotransferase (ALT) greater than 5 times the upper limit of normal

          -  ALT greater than 3 times the upper limit of normal and bilirubin greater than or equal
             to 1.5 times the upper limit of normal (with greater than 35% direct bilirubin)

          -  Subject has creatinine clearance of less than 50 mL/min via Cockroft-Gault method

          -  Recent history (less than or equal to 3 months) of any upper or lower gastrointestinal
             bleed, with the exception of anal or rectal bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Denis Cedex 01</city>
        <zip>93205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41150</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900708</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <results_first_submitted>December 12, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2014</results_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ritonavir</keyword>
  <keyword>HIV</keyword>
  <keyword>HAART</keyword>
  <keyword>darunavir</keyword>
  <keyword>antiretroviral</keyword>
  <keyword>dolutegravir</keyword>
  <keyword>GSK1349572</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 2 sequential treatment period study. In first period (Randomization phase) participants received either dolutegravir (DTG) 50 milligram (mg) or darunavir (DRV) 800 mg with ritonavir (RTV) 100 mg once daily (QD) for 96 weeks. DTG participants who completed 96 Weeks of DTG then continued to receive DTG 50 mg in Extension phase.</recruitment_details>
      <pre_assignment_details>A total of 595 participants were screened; 107 were screen failures; 488 were randomized; 485 received at least 1 dose of study medication and comprised the Intent-To-Treat exposed (ITT-E) population of which 1 participant was removed, creating the modified ITT-E population with 484 participants. 123 participants enrolled in Extension Phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTG 50 mg QD</title>
          <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
        </group>
        <group group_id="P2">
          <title>DRV 800 mg + RTV 100 mg QD</title>
          <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Extension DTG 50 mg</title>
          <description>DTG participants who successfully completed 96 Weeks of randomized phase continued to receive DTG 50 mg QD during Extension phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Phase 96 Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="242"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase Approximately 3 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTG 50 mg QD</title>
          <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
        </group>
        <group group_id="B2">
          <title>DRV 800 mg + RTV 100 mg QD</title>
          <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="242"/>
            <count group_id="B3" value="484"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Results from the mITT-E Population are presented in this report.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="10.66"/>
                    <measurement group_id="B2" value="36.2" spread="10.64"/>
                    <measurement group_id="B3" value="35.9" spread="10.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Results from the mITT-E are presented in this report.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Results from the mITT-E are presented in this report.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;50 Copies/Milliliter (c/mL) at Week 48</title>
        <description>Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) &quot;snapshot&quot; algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product</description>
        <time_frame>Week 48</time_frame>
        <population>mITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) &lt;50 Copies/Milliliter (c/mL) at Week 48</title>
          <description>Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) &quot;snapshot&quot; algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product</description>
          <population>mITT-E Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of DTG 50 mg and DRV+RTV at Week 48 can be concluded if the lower bound of a two-sided 95% confidence interval (CI) for the difference in percentages (DTG - DRV+RTV) is greater than -12%. If non-inferiority is established, superiority can be tested at the nominal 5% level based on a pre-specified testing procedure.</non_inferiority_desc>
            <p_value>0.025</p_value>
            <p_value_desc>P-value is for test of superiority.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified analysis</method_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>13.2</ci_upper_limit>
            <estimate_desc>Analysis was adjusted for the Baseline (BL) stratification factors: Baseline plasma HIV-1 RNA (&lt;=100,000 c/mL vs &gt;100,000 c/mL) and Baseline background dual NRTI therapy (ABC/3TC vs TDF/FTC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Virologic Suppression (&lt;50 Copies/mL) Through Week 48</title>
        <description>The time to viral suppression (i.e. first viral load value &lt;50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.</description>
        <time_frame>From Baseline through Week 48</time_frame>
        <population>mITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virologic Suppression (&lt;50 Copies/mL) Through Week 48</title>
          <description>The time to viral suppression (i.e. first viral load value &lt;50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.</description>
          <population>mITT-E Population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0">The DTG median time to suppression 95% CI was not estimable due to the steep increase in cumulative incidence at Day 28, so the confidence limit lines do not extend to cross the median line.</measurement>
                    <measurement group_id="O2" value="85.0" lower_limit="84.0" upper_limit="108.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &lt;400 c/mL at Week 48</title>
        <description>The percentage of participants with Plasma HIV-1 RNA &lt;400 c/mL at Week 48 was assessed MSDF, as codified by the FDA &quot;snapshot&quot; algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).</description>
        <time_frame>Week 48</time_frame>
        <population>mITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &lt;400 c/mL at Week 48</title>
          <description>The percentage of participants with Plasma HIV-1 RNA &lt;400 c/mL at Week 48 was assessed MSDF, as codified by the FDA &quot;snapshot&quot; algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).</description>
          <population>mITT-E Population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48</title>
        <description>Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
        <population>mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg OD</title>
            <description>Participants received DTG 50 mg OD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg OD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg OD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg OD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48</title>
          <description>Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
          <population>mITT-E Population.</population>
          <units>Log10 copies per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=238, 235</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                    <count group_id="O2" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="0.625"/>
                    <measurement group_id="O2" value="-2.01" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=237, 236</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="0.649"/>
                    <measurement group_id="O2" value="-2.40" spread="0.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=234, 227</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="0.653"/>
                    <measurement group_id="O2" value="-2.61" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=229, 228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="228"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="0.691"/>
                    <measurement group_id="O2" value="-2.71" spread="0.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=234, 227</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="0.765"/>
                    <measurement group_id="O2" value="-2.83" spread="0.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36, n=232, 218</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="0.715"/>
                    <measurement group_id="O2" value="-2.85" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=227, 212</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.739"/>
                    <measurement group_id="O2" value="-2.86" spread="0.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ and CD8+ Cell Counts</title>
        <description>Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 36 and 48 for CD4+ and Baseline and Weeks 4, 12, 24 and 48 for CD8+</time_frame>
        <population>mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ and CD8+ Cell Counts</title>
          <description>Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</description>
          <population>mITT-E Population.</population>
          <units>Cells per millimeters cubed (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4+ cell count, Week 4, n=237, 236</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" spread="101.36"/>
                    <measurement group_id="O2" value="75.6" spread="124.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 8, n=236, 236</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.9" spread="124.13"/>
                    <measurement group_id="O2" value="118.8" spread="142.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 12, n=234, 228</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="228"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.2" spread="120.03"/>
                    <measurement group_id="O2" value="131.8" spread="143.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 16, n=227, 227</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.8" spread="146.60"/>
                    <measurement group_id="O2" value="146.1" spread="166.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 24, n=233, 227</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.1" spread="145.85"/>
                    <measurement group_id="O2" value="164.3" spread="180.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 36, n=232, 218</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.1" spread="159.06"/>
                    <measurement group_id="O2" value="186.5" spread="183.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4+ cell count, Week 48, n=227, 212</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="227"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.8" spread="180.68"/>
                    <measurement group_id="O2" value="215.4" spread="177.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ cell count, Week 4, n=235, 235</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.4" spread="276.01"/>
                    <measurement group_id="O2" value="-3.7" spread="375.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ cell count, Week 12, n=231, 227</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.0" spread="343.81"/>
                    <measurement group_id="O2" value="-68.9" spread="373.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ cell count, Week 24, n=231, 224</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-108.0" spread="350.03"/>
                    <measurement group_id="O2" value="-132.9" spread="389.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8+ cell count, Week 48, n=224, 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-109.5" spread="360.94"/>
                    <measurement group_id="O2" value="-162.1" spread="421.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48</title>
        <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
        <time_frame>Week 48</time_frame>
        <population>mITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48</title>
          <description>The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).</description>
          <population>mITT-E Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48</title>
        <description>Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment*visit interaction and Baseline LDL cholesterol*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.</description>
        <time_frame>From Baseline through Week 48</time_frame>
        <population>mSafety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48</title>
          <description>Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment*visit interaction and Baseline LDL cholesterol*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.</description>
          <population>mSafety Population.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.041"/>
                    <measurement group_id="O2" value="0.37" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48</title>
        <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.</description>
        <time_frame>From Baseline through Week 48</time_frame>
        <population>mSafety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48</title>
          <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.</description>
          <population>mSafety Population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities</title>
        <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.</description>
        <time_frame>From Baseline through Week 48</time_frame>
        <population>mSafety Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities</title>
          <description>Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.</description>
          <population>mSafety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine Amino Transferase, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycaemia, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycaemia, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)</title>
        <description>An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA &gt;200 c/mL &gt;=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.</description>
        <time_frame>Baseline until PDVF up to Week 48</time_frame>
        <population>PDVF Genotypic Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg OD</title>
            <description>Participants received DTG 50 mg OD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg OD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg OD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg OD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)</title>
          <description>An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA &gt;200 c/mL &gt;=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.</description>
          <population>PDVF Genotypic Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48</title>
        <description>SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participants quality of life over that period.</description>
        <time_frame>Baseline, Week 4, Week 24, and Week 48</time_frame>
        <population>mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg OD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48</title>
          <description>SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participants quality of life over that period.</description>
          <population>mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=218, 210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="0.56"/>
                    <measurement group_id="O2" value="-2.19" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=222, 214</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="0.64"/>
                    <measurement group_id="O2" value="-1.65" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n= 222, 215</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.68"/>
                    <measurement group_id="O2" value="-0.77" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48</title>
        <description>The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Week 24, and Week 48</time_frame>
        <population>mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48</title>
          <description>The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, n=217, 213</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.012"/>
                    <measurement group_id="O2" value="0.02" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=224, 217</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.01" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48</title>
        <description>The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Week 24, and Week 48</time_frame>
        <population>mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48</title>
          <description>The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, n=221, 216</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="0.885"/>
                    <measurement group_id="O2" value="5.96" spread="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=224, 220</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.78" spread="0.762"/>
                    <measurement group_id="O2" value="6.95" spread="0.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48</title>
        <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
        <time_frame>Week 4, Week 24, and Week 48</time_frame>
        <population>HIVTSQ mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48</title>
          <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
          <population>HIVTSQ mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=206, 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="206"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" spread="6.43"/>
                    <measurement group_id="O2" value="52.4" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n= 211, 200</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="5.16"/>
                    <measurement group_id="O2" value="54.3" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=212, 201</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="4.60"/>
                    <measurement group_id="O2" value="54.5" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48</title>
        <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
        <time_frame>Week 4, Week 24, and Week 48</time_frame>
        <population>HIVTSQ mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48</title>
          <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
          <population>HIVTSQ mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=202, 190</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="3.61"/>
                    <measurement group_id="O2" value="25.8" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=210, 199</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="3.16"/>
                    <measurement group_id="O2" value="26.6" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=211, 201</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="3.00"/>
                    <measurement group_id="O2" value="26.6" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48</title>
        <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
        <time_frame>Week 4, Week 24, and Week 48</time_frame>
        <population>HIVTSQ mITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg QD</title>
            <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>DRV 800 mg + RTV 100 mg QD</title>
            <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48</title>
          <description>Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.</description>
          <population>HIVTSQ mITT-E Population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, n=204, 190</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.71"/>
                    <measurement group_id="O2" value="5.2" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=211, 200,</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="0.64"/>
                    <measurement group_id="O2" value="5.4" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=212, 201</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.62"/>
                    <measurement group_id="O2" value="5.4" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the available safety data from the start of the study medication up to end of study.</time_frame>
      <desc>SAEs and non-serious AEs were reported for members of the Modified Safety Population, comprised of all participants who received at least one dose of investigational product excluding one participant at one site, which was closed due to GCP non-compliance issues in another ViiV Healthcare sponsored trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTG 50mg QD</title>
          <description>Participants received DTG 50 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks. Participants were then given the opportunity to receive DTG 50 mg QD during an Extension Phase of the study.</description>
        </group>
        <group group_id="E2">
          <title>DRV 800 mg + RTV 100 mg QD</title>
          <description>Participants received DRV 800 mg + RTV 100 mg QD administered in combination with FDC dual NRTI therapy (either ABC/3TC or TDF/FTC) for 96 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Extension DTG 50 mg</title>
          <description>DTG participants who successfully completed 96 Weeks of randomized phase continued to receive DTG 50 mg QD during Extension phase</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Proctitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug use disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Bicuspid aortic valve</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Type V hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ear canal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Scleral discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="46" subjects_affected="43" subjects_at_risk="242"/>
                <counts group_id="E2" events="98" subjects_affected="74" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="242"/>
                <counts group_id="E2" events="56" subjects_affected="48" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastrointestinal erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gingival recession</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Noninfective gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Palatal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rectal lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue dry</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abscess sterile</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Thirst decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gallbladder cholesterolosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Jarisch-Herxheimer reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="242"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="242"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal chlamydia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ear infection fungal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urethritis gonococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Condyloma latum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infected fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oropharyngitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Primary syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Strongyloidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tongue fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ureaplasma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burn oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Axillary nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Penis injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Product use complaint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sports injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Campylobacter test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipids increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Parasite stool test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipid metabolism disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="242"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug use disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Libido disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tobacco abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Flat affect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Psychomotor retardation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Substance use disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Renal tubular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urethral discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Penile discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Asthenospermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ejaculation failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genital discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematospermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="242"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasal discharge discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngeal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pharyngeal ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Tonsillar exudate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="242"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Guttate psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Mucocutaneous ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash morbilliform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Bereavement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Family stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Substance use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Treatment noncompliance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="242"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

